is a startup founded in 2012 with a mission to establish a presence in the emerging clinical next-gen sequencing market. The company has introduced a user-friendly, rapid, and cost-effective human genome interpretation service through its iBinom Saas platform. This platform offers an end-to-end solution for interpreting genomes to diagnose both Mendelian and non-Mendelian diseases, tumor profiling, and drug response biomarker discovery studies. iBinom leverages Amazon EC2 and its proprietary algorithms, alongside machine learning technology, to simplify and expedite inherited disease diagnostics. The company's approach includes a unique design for medical reports. iBinom secured a $300.00K investment in a Seed Round in December 2014. With this funding, the company is poised to make impactful strides in bringing its services to the medical field and addressing the diagnostic and treatment challenges faced by seriously ill patients. The company operates within the Big Data and Biotechnology industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | $300.00K | - | 01 Dec 2014 | |
| Seed Round | $100.00K | 3 |
|
01 Sep 2013 |
No recent news or press coverage available for iBinom.
We care about your data, and we'd love to use cookies make your experience better.
